2 results match your criteria: "Atrium Health Clinical Microbiology Laboratory[Affiliation]"
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Infections.
Antimicrob Agents Chemother
April 2020
Department of Internal Medicine, Division of Infectious Diseases, Atrium Health, Charlotte, North Carolina, USA.
The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for treatment of carbapenem-resistant (CRE) infections remains unknown. This was a multicenter, retrospective cohort study of adults with CRE infections who received ceftazidime-avibactam or meropenem-vaborbactam for ≥72 hours from February 2015 to October 2018. Patients with a localized urinary tract infection and repeat study drug exposures after the first episode were excluded.
View Article and Find Full Text PDFThe Uncertain Clinical Benefit of the T2Bacteria Panel.
Ann Intern Med
June 2019
Atrium Health Clinical Microbiology Laboratory, Charlotte, North Carolina (G.A.C.).